549 results on '"Loftus, E"'
Search Results
2. Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis
3. OP06 Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND Study
4. Brief exposure to misinformation can lead to long-term false memory propensity.
5. A late Quaternary record of seasonal sea surface temperatures off southern Africa
6. Memory, but Not Memory
7. P631 Long-term safety of vedolizumab versus other biologic agents in ulcerative colitis (UC) and Crohn’s Disease (CD): Results from a large multinational prospective observational study
8. P860 The Costs of Inflammatory Bowel Diseases in High-Income Settings
9. P553 Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications
10. Comparison of infliximab with adalimumab in 827 biologic‐naïve patients with Crohnʼs disease: a population‐based Danish cohort study
11. Postoperative outcomes in vedolizumab‐treated Crohnʼs disease patients undergoing major abdominal operations
12. DOP053 Impact of concomitant immunomodulator use on vedolizumab effectiveness: a multicentre consortium propensity score-matched analysis
13. DOP051 Shorter disease duration is associated with higher response rates to vedolizumab in Crohn’s disease but not ulcerative colitis: a multi-centre consortium analysis
14. DOP009 Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis
15. DOP006 A multicentre cohort study to assess the safety of vedolizumab for inflammatory bowel disease
16. DOP004 Long-term safety of adalimumab in patients with moderate-to-severe ulcerative colitis: Interim results of a non-interventional registry, LEGACY
17. OP026 Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysis
18. OP025 Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn’s disease: a multicentre consortium propensity score-matched analysis
19. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus
20. P669 Adalimumab long-term effectiveness in adalimumab-naïve patients with Crohnʼs disease: final data from PYRAMID registry
21. P357 A multi-institutional report of postoperative outcomes in Vedolizumab-Treated patients undergoing major abdominal operations for inflammatory bowel disease
22. P263 De-novo inflammatory bowel disease after bariatric surgery: a novel association
23. Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis
24. Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease
25. A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY
26. DOP37 Efficacy and safety of filgotinib in patients with Ulcerative Colitis stratified by age: Post hoc analysis of the phase 2b/3 SELECTION and SELECTIONLTE studies
27. DOP40 Impact of corticosteroid usage on efficacy and safety outcomes in patients receiving upadacitinib for Ulcerative Colitis
28. DOP41 Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis
29. DOP44 Long-term use of ozanimod in patients with moderately to severely active Ulcerative Colitis
30. P495 Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trials
31. P377 Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study
32. P547 Early modification of inflammatory burden through treatment with vedolizumab or adalimumab is predictive of long-term treatment success in patients with Ulcerative Colitis from the VARSITY Study
33. P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from, 52-week phase, 3 study U ACHIEVE maintenance
34. DOP38 Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1
35. Letter: cytomegalovirus colitis in a patient treated with ipilimumab for metastatic melanoma – authorsʼ reply
36. Letter: anti-CTLA-4-associated colitis and inflammatory bowel disease pathogenesis – authorsʼ reply
37. Systematic review with meta-analysis: faecal diversion for management of perianal Crohnʼs disease
38. Efficacy and safety of certolizumab pegol for Crohnʼs disease in clinical practice
39. Systematic review: colitis associated with anti-CTLA-4 therapy
40. Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohnʼs disease: analyses from the 7-year PRECiSE 3 study
41. Letter: comparative efficacy of biological therapy in patients with ulcerative colitis
42. Detection rate and outcome of colonic serrated epithelial changes in patients with ulcerative colitis or Crohnʼs colitis
43. P325 Real-World Effectiveness And Safety Of Ustekinumab In Patients With Ulcerative Colitis: A Multi-Centre Study
44. DOP88 Effect of risankizumab on patient-reported outcomes in patients with Crohn’s Disease who had an inadequate response or intolerance to conventional and/or biologic treatments: Results from phase 3 MOTIVATE and ADVANCE trials
45. DOP84 Early treatment responses within 14 days of intravenous vedolizumab induction therapy for Crohn’s Disease: Post hoc analysis of patient-reported outcomes from the VISIBLE 2 study
46. DOP82 Corticosteroid-free remission of Ulcerative Colitis with filgotinib maintenance therapy: Post hoc analysis of the phase 2b/3 SELECTION study
47. P271 Evolving Targets in Ulcerative colitis: Defining Disease Clearance in the VARSITY Study
48. OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study
49. A15 EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
50. A17 EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.